Internal Medicine

University of Chicago

Questions discussed in this category

Would you consider daratumumab monotherapy as standard of care for smoldering multiple myeloma based on the AQUILA trial?

AQUILA trial - NEJM

3 Answers available

How do you approach treatment for patients with proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) with end-stage renal disease who are considering kidney transplant?

Most patients with PGNMID have no detectable disease in their marrow or blood and urine protein cannot adequately be monitored.

1 Answer available

For relapsed/refractory myeloma, how long of a disease-free interval from first autologous transplant do you recommend before considering a second autologous transplant?

1 Answer available

How would one alter therapy in a transplant-ineligible AL amyloidosis with less than a complete response to six cycles of Dara-CyBorD?

Would you continue with daratumumab maintenance per ANDROMEDA or switch regimen?

2 Answers available

Papers discussed in this category

Blood Cancer J, 2021 Jan 11

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.

N Engl J Med,

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.

Lancet Haematol,

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.

Leukemia, 2020 Jul 21

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.

Kidney international, 2018-07

Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft.

BMC nephrology, 2019-02-14

Complete biopsy-proven resolution of deposits in recurrent proliferative glomerulonephritis with monoclonal IgG deposits (PGNMIGD) following rituximab treatment in renal allograft.

The New England journal of medicine, 2024 Dec 09

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.

Blood cancer journal, 2020 Oct 16

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).

Blood advances, 2023 Nov 14

CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies.

Related Topics in Internal Medicine